Update MRONJ and perspectives of its treatment

J Stomatol Oral Maxillofac Surg. 2017 Sep;118(4):232-235. doi: 10.1016/j.jormas.2017.06.012. Epub 2017 Jul 8.

Abstract

Antiresorptive agents are widely used in catabolic bone diseases. Not only bisphosphonates but also new drugs like Denosumab may induce osteonecrosis of the jaw as a side effect. The present review describes the current effect mechanisms of commonly used antiresorptives, pathogenetic theories for the development of antiresorptive-related osteonecrosis of the jaw (ARONJ), and potential risk factors. Furthermore, diagnostic modalities and treatment options as well as new and innovative strategies are discussed. The major key factor to avoid the occurrence of ARONJ still remains the implementation of throughout preventive measures.

Keywords: ARONJ; Bisphosphonates; Denosumab; Osteonecrosis of the jaw.

Publication types

  • Review

MeSH terms

  • Bisphosphonate-Associated Osteonecrosis of the Jaw / diagnosis
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / epidemiology
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / therapy*
  • Bone Density Conservation Agents / adverse effects*
  • Denosumab / adverse effects
  • Diphosphonates / adverse effects
  • Humans
  • Oral Surgical Procedures / methods
  • Oral Surgical Procedures / trends*

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Denosumab